Iktos Joins AWS Marketplace with Makya, Its AI-Powered Drug Design Platform

Iktos, a company specializing in artificial intelligence for drug discovery, has joined the AWS Partner Network as an Advanced Technology Partner and has been accepted into the AWS ISV (Independent Software Vendor) Accelerate co-sell program. This development marks the availability of Makya, Iktos’s AI-based drug design software, on the AWS Marketplace, making the platform more accessible to pharmaceutical companies worldwide through AWS’s cloud infrastructure.

Makya Now Available on AWS Marketplace

Through its participation in the AWS ISV Accelerate program, Iktos aims to extend its reach and improve the delivery and performance of its solutions by leveraging AWS’s secure, scalable computing environment. The availability of Makya via AWS Marketplace offers pharmaceutical teams a streamlined way to integrate advanced AI into their drug discovery workflows.

Makya is a generative AI tool built by chemists to meet the practical needs of drug designers. The platform enables the rapid creation of novel, diverse, and synthetically feasible molecules that are optimized for drug discovery, helping researchers move efficiently from design to viable candidates.

“Our partnership with AWS and the inclusion of Makya on AWS Marketplace represent a significant milestone for Iktos. AWS’s secure and robust cloud infrastructure allows us to deliver Makya’s advanced drug design capabilities to pharmaceutical customers worldwide, enhancing their ability to innovate and transform drug discovery processes. The global reach, scalability, and cutting-edge analytics services provided by AWS were key factors in our decision to collaborate.”

Nicolas Do Huu, CTO & Co-Founder at Iktos

Client Success: Teijin Pharma’s Experience with Makya on AWS

The partnership has already delivered value for Iktos clients. Teijin Pharma, an early adopter of Makya, successfully deployed the software via the Iktos infrastructure hosted on AWS. This has allowed the company to access Makya’s full capabilities with greater speed and flexibility.

“Teijin Pharma has successfully implemented Makya through AWS to streamline our drug discovery processes. The synergy between Iktos’s AI platform and AWS’s reliable, scalable cloud services has allowed us to accelerate molecule design and potentially bring new therapies to the market more efficiently. In particular, Makya, whose user-friendly interface is crafted to enhance our compound design workflow, is available for users of all levels, including medicinal chemists and computational chemists. With its intuitive interface, this software allows for the design of rational compounds, as well as flexible and logical analysis and filtering, rapidly and iteratively. It prioritizes the most promising compounds and significantly contributes to enhancing creativity and productivity.”

Jun Hirata, Director, Teijin Pharma

As an Advanced Technology Partner, Iktos offers key benefits to users of Makya on AWS:

• Global Reach: Researchers can deploy and access the tool globally via AWS’s network.
• Scalable Infrastructure: AWS provides a secure, flexible environment that supports Makya’s computational requirements.
• High Performance: Users can run large-scale simulations and compound generation tasks efficiently.
• Faster Discovery Cycles: Clients like Teijin Pharma are already seeing gains in productivity and speed.

“We are excited to welcome Iktos as an Advanced Technology Partner to the ISV Accelerate program and support the global deployment of Makya. By combining Iktos’s expertise in AI-driven drug discovery with AWS’s scalable and secure cloud infrastructure, we are enabling pharma customers to accelerate their R&D efforts and achieve transformative outcomes.”

Boris Bogdan, Director of Life Sciences at AWS